文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[Ga]Ga-PSMA-11: The First FDA-Approved Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer.

作者信息

Hennrich Ute, Eder Matthias

机构信息

German Cancer Research Center (DKFZ), Division of Radiology, 69120 Heidelberg, Germany.

Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

出版信息

Pharmaceuticals (Basel). 2021 Jul 23;14(8):713. doi: 10.3390/ph14080713.

DOI:10.3390/ph14080713
PMID:34451810
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8401928/
Abstract

For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug Administration (FDA) as the first Ga-radiopharmaceutical for the PET imaging of PSMA-positive prostate cancer in 2020. This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys(Ahx)-HBED-CC with the radionuclide Ga, enabling specific imaging of tumor cells expressing PSMA. Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63d5/8401928/3df009828df5/pharmaceuticals-14-00713-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63d5/8401928/5df3ea9b6fd6/pharmaceuticals-14-00713-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63d5/8401928/3df009828df5/pharmaceuticals-14-00713-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63d5/8401928/5df3ea9b6fd6/pharmaceuticals-14-00713-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63d5/8401928/3df009828df5/pharmaceuticals-14-00713-g002.jpg

相似文献

[1]
[Ga]Ga-PSMA-11: The First FDA-Approved Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer.

Pharmaceuticals (Basel). 2021-7-23

[2]
Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.

J Nucl Med. 2016-6-3

[3]
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.

Pharmaceuticals (Basel). 2014-6-30

[4]
Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer.

J Nucl Med. 2017-10-6

[5]
Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients.

Molecules. 2015-8-14

[6]
Synthesis and evaluation of a novel urea-based Ga-complex for imaging PSMA binding in tumor.

Nucl Med Biol. 2017-12-27

[7]
Synthesis of Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced Ga as exemplified by [Ga]Ga-PSMA-11 for prostate cancer PET imaging.

Nat Protoc. 2022-4

[8]
Development and Validation of a High-Pressure Liquid Chromatography Method for the Determination of Chemical Purity and Radiochemical Purity of a [Ga]-Labeled Glu-Urea-Lys(Ahx)-HBED-CC (Positron Emission Tomography) Tracer.

ACS Omega. 2017-10-31

[9]
68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

Bioconjug Chem. 2012-3-13

[10]
Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

Eur Urol. 2016-1-18

引用本文的文献

[1]
Clinical evaluation of [Tc]Tc-PSMA-P1: a promising SPECT radiotracer for prostate cancer imaging.

RSC Adv. 2025-8-18

[2]
Enhanced NIR-II Nanoparticle Probe for PSMA-Targeted Molecular Imaging and Prostate Cancer Diagnosis.

Int J Nanomedicine. 2025-8-9

[3]
Ga Extemporaneous Preparations in Radiopharmacy.

Pharmaceutics. 2025-6-20

[4]
Peptide-Based Biomaterials as a Promising Tool for Cancer Radiotherapy.

Adv Sci (Weinh). 2025-8

[5]
Semiquantitative Analysis in PET/CT Imaging of Prostate Cancer.

J Clin Med. 2025-5-29

[6]
Development and clinical potential of F-PSiMA for prostate cancer PET imaging.

RSC Med Chem. 2025-5-9

[7]
Impact of PSMA-PET/CT on Radiotherapy Decisions: Is There a Clinical Benefit?

Cancers (Basel). 2025-4-17

[8]
Byproducts in the synthesis of [Ga]Ga-PSMA-11.

Nat Protoc. 2025-4-18

[9]
Developments in Ultrasound-Based Imaging for Prostate Cancer Detection.

Prostate. 2025-6

[10]
Preclinical Evaluation of a Novel PSMA-Targeted Agent Ga-NOTA-GC-PSMA for Prostate Cancer Imaging.

Tomography. 2025-3-7

本文引用的文献

[1]
Recent Breakthrough in Ga-Radiopharmaceuticals Cold Kits for Convenient PET Radiopharmacy.

Bioconjug Chem. 2021-3-17

[2]
Performance of [Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients.

Eur J Nucl Med Mol Imaging. 2021-8

[3]
The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging.

Eur J Nucl Med Mol Imaging. 2021-6

[4]
Multimodal imaging for radiation therapy planning in patients with primary prostate cancer.

Phys Imaging Radiat Oncol. 2018-11-5

[5]
Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.

J Nucl Med. 2021-2

[6]
Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE.

EJNMMI Radiopharm Chem. 2021-1-7

[7]
Cyclotron-based production of Ga, [Ga]GaCl, and [Ga]Ga-PSMA-11 from a liquid target.

EJNMMI Radiopharm Chem. 2020-11-12

[8]
Impact of Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.

J Nucl Med. 2020-12

[9]
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.

Lancet. 2020-3-22

[10]
The Current Status of the Production and Supply of Gallium-68.

Cancer Biother Radiopharm. 2020-3-20

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索